UroGen Pharma

📍 Princeton, United States🗓 Founded 2004👥 208 employees💰 Last funded Jun 2018
Biotechnology🌐 urogen.com
Website LinkedIn
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in UroGen Pharma?
UroGen Pharma has 1 investors on record on gritt.io.
When did UroGen Pharma last raise funding?
The most recent investment in UroGen Pharma recorded on gritt.io was in June 2018.
When was UroGen Pharma founded?
UroGen Pharma was founded in 2004.
What industry is UroGen Pharma in?
UroGen Pharma operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is UroGen Pharma based?
UroGen Pharma is headquartered in Princeton, United States.